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’BASIC RESEARCH: SEEKING KNOWLEDGE FOR THE
SAKE OF KNOWLEDGE
In 1961, a report emerged from the laboratory of inorganic
chemist Russell Drago describing the reaction of nitric oxide
(NO) with selected nucleophiles.
1 One of these was diethyla-
mine, whose reaction with NO produced a white powder of
formula 1 that, on standing exposed to air overnight, was
converted to the potent carcinogen N-nitrosodiethylamine (2)
(eq 1).
2 The authors speculated that the reaction proceeded by
the mechanism shown in Figure 1, path A, which begins by
reversing the synthesis reaction to regenerate NO from the solid
material. On reading these reports, I hypothesized that this
reaction might instead proceed by novel pathway B of Figure 1,
which begins with oxygen directly abstracting the elements of
NO
  from 1 to produce 2 plus diethylammonium nitrite.
Conﬁrmation that path B was operative would have been an
interesting theoretical advance in the area of nitrosamine forma-
tion, a research theme I was pursuing at the time. Unfortunately
for my hypothesis, however, this was not the case. NMR
experiments supported path A, revealing that 1 simply regener-
ated the NO and diethylamine in solution, with the NO then
being autoxidized to the well-known nitrosating agent N2O3,
which recombined with the free amine to form 2. This was not
the newsworthy mechanism of nitrosamine formation I had
hoped for, because everybody already knew that aerobic NO
could nitrosate amines, so we published a short account of the
study in a 1982 meeting proceedings
3 and pursued other, at the
time seemingly more relevant, facets of nitrosamine chemistry.
The picture changed dramatically in 1987 and 1988, when
publications from the biomedical sector claiming NO to be a key
eﬀector of blood vessel dilation,
4 neurotransmission in the
brain,
5 immune response,
6,7 and anticoagulant activity
8 began
toappear.Initially,Ididnotbelieve these reports, havinglearned
a lot about the nefarious face of NO through its involvement as a
metabolite and precursor of the carcinogenic N-nitroso com-
poundsIhadbeenstudying.Irealized,however,thatifanypartof
that work was credible, something really important was breaking
onto the biomedical scene.
’PROBING THE CHEMISTRY OF 1 AND ANALOGOUS
IONS AS A STARTING POINT FOR DEVELOPING NOVEL
TOOLS FOR CHEMICAL BIOLOGY RESEARCH
If reports of NO’s bioeﬀector roles were true, and if 1 and its
analogues indeed hydrolyze to produce molecular NO in solu-
tion, then one might expect these ions to be pharmacologically
active. As a platform for beginning tests of this hypothesis, my
colleagues and I started by preparing a selection of salts of
structure X-N(O)dNO
  M
+ and systematically cataloguing
their physicochemical properties. Many were found to precipi-
tate in pure form from solutions of the X-H precursor on expo-
sure to gaseous NO under basic conditions, although success
sometimes proved to be quite dependent on empirically choos-
ing the correct solvent. Exchanging the dialkyammonium ion of
1 and homologues for sodium tended to improve the salts’ shelf
life, with many examples proving indeﬁnitely stable as solids at
4 C. Structural studies conﬁrmed the substantial double bond
character of the N N linkage of many X-N(O)dNO
  ions,
with the oxygens being cis to one another; this and other fea-
tures of their structures led to their formal designation as
“diazeniumdiolates”,
9 although earlier nomenclature proposals
referring to them as “NOC compounds” or “NONOates” con-
tinue in common use. These salts proved to be UV-active, with a
strongchromophoreat∼250nmandεmaxof∼7mM
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ABSTRACT: Here I show that a “pure” research project, seemingly totally
lacking in practical application when it was ﬁrst published, can years later
spark a whole new scientiﬁc ﬁeld with the potential to revolutionize clinical
practice. A 1961 publication describing adducts of nitric oxide (NO) with
certain nucleophiles attracted little notice at the time, but later work
showing that the adducts could be hydrolyzed to regenerate the NO in
bioactive form has provided the foundation for a host of biomedical applications. Crucial to the discovery of widely used tools for
studying NO’s chemical biology as well as for the design of a variety of promising therapeutic advances has been the increasingly
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the absence of electronic interaction with X, allowing for con-
venient characterization of their solution chemistry. They react
withcopper(II)toproducecoordinationcomplexesinwhichthe
metal binds the ligand’s two oxygens without oxidizing it,
10
although reductive nitrosylation has been implicated in the
reactions of diazeniumdiolate ions with other metal centers.
11,12
ExamplesforwhichXisasecondaryamineresiduewerefound
to generate NO in yields approaching the theoretical 2 mol/mol
atphysiologicaltemperatureandpH,withreproduciblehalf-lives
rangingfrom2sto20h,dependingonthestructureoftheamine
moiety (Figure 2).
13 The mechanism of the cleanly ﬁrst-order
(at constant pH) hydrolysis was elucidated, showing that the
favoredequilibriumprotonationsiteistheterminaloxygen,while
the kinetically signiﬁcant tautomer has the proton at the amino
nitrogenofthediazeniumdiolatedsecondaryamines.
14Fromthe
standpointofstoichiometry,theacid-catalyzedhydrolysisreaction
was conﬁrmed to consume acid and slow itself down as the pH
climbsintheabsenceofproperbuﬀeringcapacity.Mediumeﬀects,
suchasmicellarencapsulationandliposomeformation,havebeen
reported to aﬀect hydrolysis rates, sometimes dramatically.
15
Examples of X-N(O)dNO
  ions for which X is carbon, oxygen,
sulfur, or a primary amino group were also studied; they showed
very similar structural and ultraviolet spectral characteristics,
9
though their reactivity patterns were much more diverse than
those of the well-behaved secondary amine analogues, often
generating little to no NO on hydrolysis, for example.
Two features of these fundamental chemistry studies set the
diazeniumdiolate ions apart as advantageous tools for investigat-
ing the chemical biology of NO:
￿ In contrast to other NO donors, they require no redox
activation, releasing NO at repeatable ﬁrst-order rates on
simple dissolution in buﬀered aqueous ﬂuids, cell culture
media, or organ baths.
￿ ThebroadarrayofreproducibleNOgenerationratesallows
researchers toprobe theeﬀectsofexposure toshortpuﬀsof
thebioeﬀector,tonear-steadystateﬂuxes,andtomanyhalf-
lives of NO release in between.
’PREDICTING BIOLOGICAL EFFECTS BASED ON A
KNOWLEDGE OF THE DIAZENIUMDIOLATES’
PHYSICOCHEMICAL PROPERTIES
Ofspecialnotewastheﬁndingthatdataontherateandextent
of NO release in simple buﬀers could be used for quantitatively
predicting biological outcomes. Figure 3 illustrates an early
example. Knowing that NO had been identiﬁed as the endothe-
lium-derived relaxing factor,
4 we chose a set of ﬁve physico-
chemically diverse ionic diazeniumdiolates, determined their
hydrolysis rate constants, measured the number of moles of
NO that were produced on hydrolyzing one mole of each,
studied their eﬀe c t so nb l o o dv e s s e ld i l a t i o ni na no r g a nb a t h ,
andpublishedapaperin1991showinghowthephysicochemical
parameters could be plugged into an equation that quantitatively
correlated with vasodilatory activities in this series of com-
pounds.
16
As this increasingly reﬁned understanding of the basic chem-
istry and its pharmacological implications was developing, col-
leagues in the biomedical realm became interested in studying
theirphysiologicaleﬀectsinvivo.Cardiologist colleagues showed
that the 2-min half-life for DEA/NO (6) in physiological buﬀer
translatedtoaprofoundbutbriefdropinbloodpressureonbolus
Figure 1. Two theoretically possible mechanisms by which diazenium-
diolate salt 1 can be converted to nitrosamine 2.
Figure 2. Structures of selected diazeniumdiolate salts and zwitterions,
along with their half-lives in 0.1 M phosphate at pH 7.4 and 37 C. Each
of these generates close to the theoretical 2 mols of NO per mole of
anionic diazeniumdiolate. The ∼5- to 50-min half-life for 9 is attribu-
table to a contribution from a substrate-squared term to the rate
equation, i.e., to formation of a less reactive dimer as the concentration
is increased.
14
Figure3. Observedmaximalinvitrovasodilatorypotencies(1/EC50)of
ﬁve ionic diazeniumdiolates correlated highly (r = 0.995) with theore-
tical values computed from the compounds’ rates and extents of NO
release. (For details of the calculation, see ref 16).1149 dx.doi.org/10.1021/cb200274r |ACS Chem. Biol. 2011, 6, 1147–1155
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intravenousadministrationinrabbits,while10-foldgreaterdoses
of the longer-lived analogue SPER/NO (9) had a blunted
immediate eﬀect but one that was correspondingly much more
prolonged.
17 Similarly, the extent and time course of these
agents’ anticoagulant action in vivo closely matched predictions
based on their solution chemistry.
18
These studies showing the surprising extent to which the
biological properties quantitatively matched expectation based
on the fundamental chemistry in turn elicited interest among
clinicians in possible therapeutic strategies. Neurosurgeons
studying models of cerebral vasospasm following subarachnoid
hemorrhage showed that intracarotid infusions of the 2-min
compound DEA/NO (6) just upstream from the aﬀected vessel
inducedthedesiredvasodilation.
19Alternatively,polymerblends
of the 20-h NO donor DETA/NO (10) were shown to prevent
vasospasm in a rat femoral artery model.
20 In a vascular surgery
application, ionically diazeniumdiolated materials applied to the
outside of rat carotid arteries undergoing balloon angioplasty
dramatically improved healing at the inner surface of the vessel,
relative to untreated controls.
21
’PROTECTING GROUP STRATEGIES AND THE DESIGN
OF PRODRUGS FOR INTERNAL USE
Spontaneous generation of NO can be beneﬁcial for the kinds
of therapeuticapplicationsmentionedabove, but inmostcases it
is imperative to target the NO selectively to the given tissue or
cell type where it is needed without exposing the myriad other
NO-sensitive bodily compartments. One convenient means of
doing this is to take advantage of the diazeniumdiolate ions’
inherent nucleophilicity to generate neutral prodrug forms.
22
Initial studies with simple methylating and ethylating agents
showed that alkylation occurred at the terminal oxygen (O
2)o f
the X-N(O)dNO
  ion, in contrast to an earlier structural
assignment that erroneously placed the alkyl group on the other
oxygen; the N N linkage consistently had even more double
bond character than was seen in the corresponding ionic starting
material, with the oxygens again being cis to one another.
22 The
alkylation products proved remarkably stable toward oxidation.
With a functional group consisting of three sequential nitrogens,
two of which are oxygenated, one might have expected other-
wise; nevertheless, no problems were seen in subjecting them to
copper-mediated Click chemistry
23 or sodium periodate/ruthe-
nium trichloride-induced oxidation of a methylene group to a
carbonyl.
24 Diazeniumdiolate ions can be sulfonated at the O
2-
position,
25 but the corresponding acylated analogues have so far
deﬁed attempts to isolate them.
SNAr studies showed anionic diazeniumdiolate DEA/NO (6)
to be intermediate between chloride and ﬂuoride in its reactivity
with 1-halo-2,4-dinitrobenzenes.
26 The resulting O
2-arylated
diazeniumdiolates hydrolyzed smoothly in base.
26 These aryl
derivatives also generate NO on reaction with the nucleophilic
thiol group of glutathione (exempliﬁed in Figure 4) and have
beenwidelystudied fortheirpotentialuseasanticanceragents.
27
Initial hypotheses in this area focused on their potential to
selectively remove highly NO-sensitive leukemia cells from the
bloodstream without inﬂicting collateral toxicity in their normal
hematopoietic counterparts,
28 but their potential anticancer
activityhas,forreasonsthatremaintobefullyelucidated, proven
far more general than that. In studies that will be reviewed in
detail elsewhere, our lead O
2-arylated diazeniumdiolate JS-K
(11) has moved into the late preclinical stage of evaluation as a
broad-spectrum anticancer drug candidate, active in numerous
Figure 4. Activation of O
2-arylated diazeniumdiolate JS-K (11)a sa n
NO donor by reaction with the thiol-containing peptide glutathione
(GSH).
27
Figure 5. Base-induced removal of glucose protecting groups for
preparation of NO-releasing diazeniumdiolated poly(urethane) (from
ref 31).1150 dx.doi.org/10.1021/cb200274r |ACS Chem. Biol. 2011, 6, 1147–1155
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in vivo rodent models of cancer including leukemia,
28 multiple
myeloma,
29 and tumors of the prostate,
28 liver,
30 and lung.
27
O
2-Glycosylation has also proven advantageous as a diaze-
niumdiolate protecting group strategy. O
2-Glucosylated DEA/
NO was found to resist hydrolysis in neutral and acidic condi-
tions but to hydrolyze remarkably rapidly in base.
31 This
property proved useful during preparation of poly(urethane)s
bearing ionic diazeniumdiolate groups. By O
2-glucosylating
monodiazeniumdiolated piperazine and attaching its other
nitrogen via a linker to the diol segment of the poly(urethane)
backbone, the polymer could be processed through various
heating and other steps that the ionic form could not survive,
then treated with base to remove the saccharide residues and
regeneratethecapacityforNOrelease(Figure5).
31Additionally,
preliminary work with small-molecule O
2-glycosylated diaze-
niumdiolates has revealed their possible utility in antimicrobial
applications.
32
Diazeniumdiolate ions can also be O
2-vinylated, as illustrated
in Figure 6. The prototype in this series is V-PYRRO/NO
(12, Figure 6), designed and shown to be oxidatively cleaved by
cytochrome P450 enzymes concentrated in the liver to release
NO selectively in that organ, with minimal eﬀects elsewhere.
33
This strategy has shown considerable promise for treating fulmi-
nant liver failure,
33 acetaminophen toxicity,
34 and the ischemia/
reperfusion injury that accompanies organ transplantation.
35
Interestingly, the synthesis of O
2-vinylated derivatives as
outlined in Figure 6 failed on attempted application to a pri-
mary amine diazeniumdiolate. In this case, the main product on
treating the O
2-(2-bromoethyl)ated intermediate with base
resulted from a cyclization reaction instead of dehydrohalogena-
tion, as documented in the NMR spectra of Figure 7. This
reaction provided the ﬁrst clear evidence that cis-to-trans iso-
merizationabouttheN(O)dNObondwaspossible.Theoretical
and experimental studies revealed that the barrier to such
isomerization dropped from a prohibitive ∼40 kcal/mol for
the neutral molecule to an easily accessible value of ∼20 kcal/mol
on ionization of the N H bond.
36 The pKa for this process was
estimated to be 12.4, lower than that needed to ionize the C H
bond en route to dehydrohalogenation.
To accomplish the conversion of primary amine diazenium-
diolate 13 to the desired vinyl derivative 14, two new diaze-
niumdiolate protecting groups were developed and applied
a ss h o w ni nF i g u r e8 .
37 Reaction of IPA/NO anion with
(triisopropylsilyl)oxymethyl chloride (TOM-ylation) protected
the O
2-position, stabilizing and solubilizing IPA/NO while the
methoxymethyl (MOM) group was installed at the amino
nitrogen to render it non-nucleophilic and prevent ring closure.
Fluoride-induced removal of the TOM group in the presence of
2-bromoethyl triﬂate led to an O
2-bromoethylated diazenium-
diolate that on treatment with Verkade’s base followed by acid-
induced removal of the MOM group produced the desired O
2-
vinylation product 14.
37
Figure 6. Synthesis and metabolism of V-PYRRO/NO (12), an O
2-
vinylated diazeniumdiolate that is activated for NO release by cytoch-
romes P450.
Figure 7. Proton spectra showing the conversion of the Z diazenium-
diolate structure in panel A at time zero to the cyclic E derivative of
panel C after 2 h at 0 C in basic D2O/methanol-d4 solution. Panel B
shows the spectrum of the reaction mixture at the 15-min time point;
note the line-broadening associated with the Z to E interconversion
barrier (from ref 36).
Figure 8. Use of TOM and MOM protecting groups in the synthesis
of V-IPA/NO (14) (ref 37).1151 dx.doi.org/10.1021/cb200274r |ACS Chem. Biol. 2011, 6, 1147–1155
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MOM-ylation at the O
2-position instead of N results in less
hydrolytically sensitive diazeniumdiolates whose rates of spon-
taneous NO release are generally much slower than those of
thecorresponding ions.Anexample isdiazeniumdiolatedbovine
serum albumin, which produces about 40 mols of NO per mole
of protein with a half-life of about 3 weeks.
38 When placed in
the pericardial sac surrounding the heart to suﬀuse the coronary
arteries of pigs undergoing balloon angioplasty, this material not
only reduced the cellular overgrowth that leads to narrowing of
the arterial lumen but also beneﬁcially remodeled the vessel by
ﬁlling in the cracks in the wall that result from such balloon
overstretch.
39
Important synthetic opportunities were opened up when the
sulfur analogue of the MOM group (MeSCH2
  instead of
MeOCH2
 ) was introduced at the O
2-position. Treatment of
the resulting thio-MOM derivative with sulfuryl chloride gives
the corresponding O
2-chloromethyl compound, whose chloride
can be displaced by carboxylate ions to produce a variety of
esterase-sensitive prodrugs.
40 Among the important mutual
prodrugs made possible using this strategy is a hybrid molecule
whose hydrolysis yields aspirin and NO concurrently; this
NONO-aspirin was similar to aspirin itself in terms of anti-
inﬂammatory activity but largely devoid of aspirin’s ulcerogenic
side eﬀects.
41
Attaching esterase-sensitive protecting groups at the O
2-
position has proven especially illuminating. Acetoxymethylating
PYRRO/NO (4) generates a prodrug that is relatively stable in
cell culture media but that enzymatically hydrolyzes rapidly once
inside the cell to generate a concentrated intracellular ﬂux of
diazeniumdiolate ions whose antiproliferative eﬀects on the cells
are2to3ordersofmagnitudemorepotentthanisseenwhenthe
unprotected ionic diazeniumdiolate is dissolved directly in the
medium.
42Aparticularlyinterestingeﬀectofacetoxymethylation
is described in the next section.
’FROM NO TO HNO
Our initial 1991 study of vasodilatory activity on the part of
ﬁve structurally diverse diazeniumdiolates (Figure 3) included
the primary amine derivative IPA/NO (13), but this compound
was both relatively unstable and much less potent as an NO
generator and vasodilator than its secondary amine analogues.
16
For this reason, it remained little studied until news of the
biological activities of nitroxyl (HNO), the one-electron reduc-
tion product of NO, began to break some years later.
43 45 Of
special importance in the present connection was a 2005 paper
by Miranda and colleagues addressing the following question: if
IPA/NO (13) produced only 36% of the theoretical amount of
NO on hydrolysis,
16 what happened to the other 64%? The
answer: the missing nitrogenous product was HNO.
46
To study the utility of diazeniumdiolated primary amines as
HNO donors, the problem of their instability had to be over-
come.Theprototypeinthisseries,IPA/NO(13),hasatendency
to decompose on isolation and storage, sometimes producing a
mixture of the corresponding diazoate plus other decomposition
products that on visual inspection is indistinguishable from pure
IPA/NO but at other times disintegrates explosively without
warning or apparent provocation.
This problem can be largely controlled by exactingly avoiding
excesses of acids and bases in the freshly synthesized material,
47
but conversion to stable and rigorously puriﬁable O
2-substituted
derivatives has provided a more general solution. Alkylation of
the ionic diazeniumdiolates occurs preferentially at the O
2-
position,
48 providing such stable derivatives. The resulting
RHN-N(O)dN-OR species proved to be an ambident nucleo-
phile under basic conditions, undergoing alkylation at either end
oftheN N Nsystem.
49MOM-ylationof13ledtoanN,Obis-
substituted product in the presence of excess derivatizing agent,
with the O
2-monosubstituted intermediate also being isolable;
13 could also be O
2-glycosylated.
48
Acetoxymethylation of IPA/NO unveiled some properties
that were especially intriguing from the drug discovery point of
view.
50 One was that the product hydrolyzed spontaneously in
the absence of esterase with a half-life of 41 min at physiological
temperature and pH, an order of magnitude longer than that
of IPA/NO
50 and thus a considerable step toward the goal of
Figure 9. Partitioning of a diazeniumdiolated primary amine anion
between its NO- and HNO-generating hydrolysis pathways (adapted
from ref 51).
Figure 10. Spontaneous hydrolysis of the “pure” HNO donor AcOM-
IPA/NO (from ref 50).1152 dx.doi.org/10.1021/cb200274r |ACS Chem. Biol. 2011, 6, 1147–1155
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providinganarrayofreliablehalf-lives foruseasresearchtoolsin
studying the chemical biology of HNO, much as has been the
case with the NO donors discussed above.
Theothermajorsurprisewasthathydrolysisofacetoxymethy-
latedIPA/NOintheabsenceofesteraseproducedHNOwithout
cogenerating NO.
50 We had expected the reactionto proceed by
straightforwardesterhydrolysistoproduce13,whichwouldthen
hydrolyze according to the mechanism outlined in Figure 9,
which involves generation of similar ﬂuxes of NO and HNO
according to the indicated competing pathways.
51 Prodrug 15’s
behavior as a “pure” HNO donor has been ascribed to the
mechanism shown in Figure 10.
50 Future work will seek to
embellishonthischemistryasaplatformforproducingimproved
HNO donor research tools and drugs.
’TACKLING THE NITROSAMINE TOXICITY ISSUE
Having begun researching diazeniumdiolates by studying
themasprecursorsforcarcinogenicnitrosamines(Figure1),
3we
realized from the outset that this possible source of toxicity
must be dealt with head-on during any eﬀort to reap practical
beneﬁts from their chemistry. One way to do this is to employ
diazeniumdiolates whose corresponding N-nitroso derivatives
are considered noncarcinogenic; an example is PROLI/NO
(3, Figure 2),
52 whose potential metabolite N-nitrosoproline is a
normal constituent of human urine that has failed to induce
tumors in any of the long-term toxicity studies published so
far.
53 59 Another strategy is to attach the diazeniumdiolate
functional group to primary amines or carbon-based nucleo-
philes, though care must still be taken to identify the byproducts
of NO release and avoid their toxicity.
Yet another approach is to tie the NO-releasing moiety
covalently to insoluble materials that limit NO exposure only
to the cells and tissues withwhich they are inimmediate physical
contact while at the same time preventing release of any
byproduct including nitrosated species into the surrounding
medium. An example that combines the latter two approaches
is diazeniumdolated poly(acrylonitrile) (“PAN/NO”), whose
synthesis and structure are shown in Figure 11.
60 In addition
to poly(urethane)(Figure 5) and poly(acrylonitrile), other in-
soluble materials whose surfaces can be beneﬁcially converted
to NO-releasing form for a variety of antiplatelet, antimicrobial,
and wound healing applications by covalently diazeniumdiolat-
ing them include poly(ethyleneimine),
61 silicone rubber,
62 and
silicon-based hydrogels.
63
Studies of an O-alkylated diazeniumdiolate’s photochemistry
led to the surprising ﬁnding that its primary photoproducts
resulted from cleavage of the formal N N double bond to form
the corresponding nitrosamine plus an O-nitrene.
64 Although
photochemical nitrosamine formation can be largely overcome
by judicious selection of O
2-substituents that channel the reac-
tion toward NO generation,
65 the ﬁndings reinforce the impor-
tance of excluding light as well as other potentially destructive
stimuli during synthesis and storage so as to avoid unwanted
contamination by impurities in general and carcinogenic nitro-
samines in particular.
’SOME REMAINING QUESTIONS
Many questions about diazeniumdiolate chemistry remain to
beansweredifwearetorealizethefullinherentpotentialofthese
compounds as tools for researching the chemical biology of NO
and HNO as well as for rationally designing biomedical innova-
tions. Below is a selection for your consideration and, hope-
fully, input:
￿ How can it be explained that amines generally react
smoothly with NO, whereas water and hydroxide appar-
ently do not? The product of a water/hydroxide diaze-
niumdiolation reaction would be Angeli’s salt [NaO-
N(O)dNONa], an HNO donor that is synthesized by
nitrating hydroxylamine. Like most other ionic diazenium-
diolates, Angeli’s salt is increasingly stabilized as the pH is
raised, such that if it were to be formed in 1 M solutions of
sodium hydroxide in contact with 3 atm of NO it would
be spectrophotometrically detectable. But this does not
happen. Why not?
￿ What are the structural and stereoelectronic determi-
nants of the partition between the NO and HNO
generation pathways in the primary amine diazenium-
diolate series? Are the results for IPA/NO (13), which
generates substantial amounts of both NO and HNO on
hydrolysis at physiological pH (Figure 9), typical for this
series of ions? Perhaps future structure variation studies
will reveal analogues with NO- or HNO-only buﬀer
hydrolysis proﬁles among the diazeniumdiolated primary
amine anions.
￿ What are the structural and stereoelectronic determi-
nants of hydrolysis half-life? I ﬁnd this to be an enduring
mystery. Some generalizations are possible, with for ex-
ample diazeniumdiolated pyrrolidines having relatively
shorter lifetimes in solution, but how can the tremendous
spread seen among the diazeniumdiolated di- and poly-
amines [e.g., 1 min for MAHMA/NO (5) and 1 day for
DETA/NO(10)] be explained? My answer so far has been
torelycompletelyontheempiricalapproach—synthesizea
new compound and determine its hydrolysis rate experi-
mentally—but I’m hopeful that someone will someday
establishameansofrationallypredictingsuchpropertiesin
advance.
’CONCLUSION
I hope that what I have written has piqued your imagination.
Much remains to be done if the full potential of the science
presented here is to be realized, both in further probing the basic
chemistry of the diazeniumdiolates, in using the knowledge thus
gainedtodesignadditionallyimprovedtoolsforchemicalbiology
research, and in engineering important advances in medical
practice. I am convinced that there are lives to be saved in the
Figure 11. Diazeniumdiolation of poly(acrylonitrile) (PAN), a water-
insoluble polymer that generates NO only at its surface while retaining
all byproducts of its spontaneous hydrolysis within the solid polymer
matrix (from ref 60).1153 dx.doi.org/10.1021/cb200274r |ACS Chem. Biol. 2011, 6, 1147–1155
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technology described here and would warmly welcome your
participation in the eﬀort to exploit its full promise.
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